Tvardi Therapeutics (TVRD) Retained Earnings (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Retained Earnings of $131.7 million for Q1 2026, up 1646762.5% sequentially from $8000.0 in Q4 2025, and up 117.32% YoY from $60.6 million in Q1 2025.
Tvardi Therapeutics (TVRD) Retained Earnings (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Retained Earnings for 14 years, with the latest figure at $131.7 million in Q1 2026.
- Quarterly Retained Earnings rose 117.32% year-over-year to $131.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131.7 million (up 117.32% YoY) and the FY2025 annual result came in at $8000.0, up 100.01% from the prior year.
- Retained Earnings grew to $131.7 million in Q1 2026 per TVRD's latest filing, from $8000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $131.7 million in Q1 2026 and troughed at -$760.5 million in Q1 2025.
- A 5-year average of -$337.8 million and a median of -$512.7 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings sank 53589400.0% in 2022, then surged 117.32% in 2026.
- Over 5 years, Retained Earnings stood at -$566.2 million in 2022, then retreated by 20.93% to -$684.7 million in 2023, then jumped by 86.53% to -$92.2 million in 2024, then surged by 100.01% to $8000.0 in 2025, then jumped by 1646762.5% to $131.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $131.7 million, $8000.0, and -$103.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 132.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131.75 Mn |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | -103.20 Mn |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -760.52 Mn |
| Dec 31, 2024 | -92.24 Mn |
| Sep 30, 2024 | -747.93 Mn |
| Jun 30, 2024 | -121,000.00 |
| Mar 31, 2024 | -191,000.00 |
| Dec 31, 2023 | -684.75 Mn |
| Sep 30, 2023 | -652.41 Mn |
| Jun 30, 2023 | -624.38 Mn |
| Mar 31, 2023 | -592.90 Mn |
| Dec 31, 2022 | -566.23 Mn |
| Sep 30, 2022 | -535.89 Mn |
| Jun 30, 2022 | -512.71 Mn |
| Mar 31, 2022 | -1.72 Mn |
| Dec 31, 2021 | -358,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -5,000.00 |